[go: up one dir, main page]

MX2011011489A - Derivados de isoxazol-piridina. - Google Patents

Derivados de isoxazol-piridina.

Info

Publication number
MX2011011489A
MX2011011489A MX2011011489A MX2011011489A MX2011011489A MX 2011011489 A MX2011011489 A MX 2011011489A MX 2011011489 A MX2011011489 A MX 2011011489A MX 2011011489 A MX2011011489 A MX 2011011489A MX 2011011489 A MX2011011489 A MX 2011011489A
Authority
MX
Mexico
Prior art keywords
isoxazole
pyridine derivatives
present
cognitive
gaba
Prior art date
Application number
MX2011011489A
Other languages
English (en)
Inventor
Roland Jakob-Roetne
Andrew Thomas
Matthew C Lucas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2011011489A publication Critical patent/MX2011011489A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a derivados de isoxazol-piridina de la fórmula I, que tienen afinidad y selectividad hacia el receptor tipo cx5 de GABA A, a su fabricación, a las composiciones farmacéuticas que los contienen y a su uso como medicamentos. Los compuestos activos de la presente invención son útiles como un mejorador cognitivo o para el tratamiento terapéutico y/o profiláctico de los trastornos cognitivos semejantes a la enfermedad de Azheimer.
MX2011011489A 2009-05-05 2010-04-28 Derivados de isoxazol-piridina. MX2011011489A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09159457 2009-05-05
PCT/EP2010/055695 WO2010127976A1 (en) 2009-05-05 2010-04-28 Isoxazole-pyridine derivatives

Publications (1)

Publication Number Publication Date
MX2011011489A true MX2011011489A (es) 2011-11-18

Family

ID=42371365

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011489A MX2011011489A (es) 2009-05-05 2010-04-28 Derivados de isoxazol-piridina.

Country Status (12)

Country Link
US (1) US8415379B2 (es)
EP (1) EP2427456B1 (es)
JP (1) JP5466292B2 (es)
KR (1) KR101367012B1 (es)
CN (1) CN102414206B (es)
AU (1) AU2010244553A1 (es)
BR (1) BRPI1013844A2 (es)
CA (1) CA2760166C (es)
IL (1) IL216007A0 (es)
MX (1) MX2011011489A (es)
SG (1) SG175867A1 (es)
WO (1) WO2010127976A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2457569A1 (en) * 2010-11-05 2012-05-30 F. Hoffmann-La Roche AG Use of active pharmaceutical compounds for the treatment of central nervous system conditions
SG10201509163VA (en) * 2010-11-05 2015-12-30 Hoffmann La Roche Use Of Active Pharmaceutical Compounds For The Treatment Of Central Nervous System Conditions
CA2840396C (en) * 2011-06-27 2020-07-14 Merial Limited Amido-pyridyl ether compounds and compositions and their use against parasites
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
JP6223443B2 (ja) 2012-06-26 2017-11-01 サニオナ・エイピイエス フェニルトリアゾール誘導体及びｇａｂａａ受容体複合体を調節するための該フェニルトリアゾール誘導体の使用
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001280A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
KR20150033678A (ko) 2012-06-26 2015-04-01 사니오나 에이피에스 페닐 트리아졸 유도체 및 이의 gabaa 수용체 복합체 조절용 용도
ES2661437T3 (es) 2013-06-21 2018-04-02 Zenith Epigenetics Corp. Nuevos compuestos bicíclicos sustituidos como inhibidores de bromodominio
SG10201710705UA (en) 2013-06-21 2018-02-27 Zenith Epigenetics Ltd Novel bicyclic bromodomain inhibitors
EA201690087A1 (ru) 2013-07-31 2016-08-31 Зенит Эпидженетикс Корп. Новые квиназолиноны как ингибиторы бромодомена
WO2016087942A1 (en) * 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridines as bromodomain inhibitors
WO2016087936A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridinones as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
CN107406438B (zh) 2014-12-17 2021-05-14 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
EP3479696B1 (en) * 2016-06-27 2021-06-09 Moghu Research Center Ltd. Pyridine-based compound including isoxazoline ring, and use thereof as herbicide
EP3551627B1 (en) 2016-12-08 2022-02-16 F. Hoffmann-La Roche AG New isoxazolyl ether derivatives as gaba a alpha5 pam
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
KR20240005848A (ko) 2021-05-05 2024-01-12 유니버시티 칼리지 카디프 컨설턴츠 리미티드 인지 장애의 치료에 유용한 헤테로아릴 화합물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3525205A1 (de) 1984-09-11 1986-03-20 Hoechst Ag, 6230 Frankfurt Pflanzenschuetzende mittel auf basis von 1,2,4-triazolderivaten sowie neue derivate des 1,2,4-triazols
GB9808663D0 (en) 1998-04-23 1998-06-24 Merck Sharp & Dohme Therapeutic agents
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
IT1314191B1 (it) 1999-10-18 2002-12-06 Recordati Chem Pharm Derivati isossazolcarbossamidici
US6511987B1 (en) 1999-11-12 2003-01-28 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
GB0108475D0 (en) 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
IL159697A0 (en) 2001-07-05 2004-06-20 Synaptic Pharma Corp Substituted anilinic piperidines as mch selective antagonists
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
JP2005518357A (ja) 2001-11-20 2005-06-23 イーライ・リリー・アンド・カンパニー ベータ３アドレナリンアゴニスト
GB0128160D0 (en) 2001-11-23 2002-01-16 Merck Sharp & Dohme Novel compounds
US7319109B2 (en) 2002-11-22 2008-01-15 Smith Kline Beecham Corporation Farnesoid X receptor agonists
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
ATE397601T1 (de) 2004-06-01 2008-06-15 Hoffmann La Roche Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors
JP2008502687A (ja) 2004-06-14 2008-01-31 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
AU2005291540B2 (en) 2004-10-01 2008-06-19 F. Hoffmann-La Roche Ag Hexafluoroisopropanol substituted ether derivatives
EP1812427A4 (en) 2004-10-15 2009-10-14 Scripps Research Inst FATTY ACID AMIDE HYDROLASE OXADIAZOLE KETONE INHIBITORS
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
WO2007009274A2 (de) 2005-07-20 2007-01-25 Prospective Concepts Ag Pneumatisch verstellbare seitenwangen für fahrzeugsitze
CA2623043A1 (en) * 2005-09-19 2007-04-12 F. Hoffman-La Roche Ag Isoxazolo derivatives as gaba a alpha5 inverse agonists
US7334639B2 (en) * 2005-09-30 2008-02-26 M-I Llc In-situ solidification of invert emulsion fluids to form gas tight annular barrier
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
ES2374165T3 (es) 2005-12-19 2012-02-14 Glaxosmithkline Llc Agonistas del receptor x farnesoide.
EP1984360B1 (en) 2006-02-03 2014-01-15 Eli Lilly & Company Compounds and methods for modulating FX-receptors
JP2007230909A (ja) 2006-03-01 2007-09-13 Univ Of Tokyo 置換イソキサゾール誘導体
CA2651857A1 (en) * 2006-05-31 2007-12-06 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
CA2707648C (en) * 2007-12-04 2014-08-12 F. Hoffmann-La Roche Ag Isoxazolo-pyridine derivatives
BRPI0820649A2 (pt) * 2007-12-04 2015-06-16 Hoffmann La Roche Derivados de isoxazalo-pirazina
US7943619B2 (en) * 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives

Also Published As

Publication number Publication date
US8415379B2 (en) 2013-04-09
EP2427456B1 (en) 2020-02-05
EP2427456A1 (en) 2012-03-14
AU2010244553A1 (en) 2011-12-01
CA2760166C (en) 2017-07-18
KR20120018349A (ko) 2012-03-02
CA2760166A1 (en) 2010-11-11
WO2010127976A1 (en) 2010-11-11
SG175867A1 (en) 2011-12-29
BRPI1013844A2 (pt) 2016-04-12
CN102414206B (zh) 2014-11-05
JP5466292B2 (ja) 2014-04-09
US20100286132A1 (en) 2010-11-11
IL216007A0 (en) 2012-01-31
CN102414206A (zh) 2012-04-11
JP2012526071A (ja) 2012-10-25
KR101367012B1 (ko) 2014-03-14

Similar Documents

Publication Publication Date Title
MX2011011489A (es) Derivados de isoxazol-piridina.
MX2011007774A (es) Derivados de isoxazol-isoxazol e isoxazol-isotiazol.
MX2011011273A (es) Derivados de isoxazol-pirazol.
MX2011011477A (es) Derivados de isoxazol-piridazina.
MX2009014001A (es) Derivados de isoxazol-imidazol.
EA200901373A1 (ru) Аминогетероциклические соединения
TW201144302A (en) 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
MX2011011490A (es) Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos.
IN2012DN00766A (es)
MX2013004588A (es) Derivados de triazol y su uso para trastornos neurologicos.
MX2010004026A (es) Piperidino-dihidrotienopirimidinas sustituidas.
WO2007048801A3 (en) Sexual desire enhancing medicaments comprising benzimidazolone derivatives
DE602007001893D1 (en) Aryl-4-ethinylisoxazolderivate
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
HK1154587A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
UA93872C2 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
MX2011007772A (es) Derivados de isoxazol/o-piridina con enlazador etilo y etenilo.
TR201909277T4 (tr) Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
MX2014003408A (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1).
MX2012010658A (es) Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa.
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
MX2011011303A (es) Derivados de isoxazol.

Legal Events

Date Code Title Description
FG Grant or registration